Altered PD-L1 Expression in Non-Small Cell Lung Cancer Patient After Induction Chemotherapy: A Case Report

Fadi Nasr, Ahmad Al Ghoche, Saada Diab, Souheil Hallit, Moussa Riachi

Abstract


Targeting the immune checkpoint of programmed death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) with immunotherapy has improved the treatment of many tumors including non small cell lung cancer (NSCLC). Checking PD-L1 status must be done during the course of therapy. Changes of PD-L1 status with therapy have been described in several cancer subtypes with different treatment modalities including chemotherapy and immunotherapy. Here we present a case report of a locally advanced squamous lung carcinoma patient presenting a decrease of PD-L1 level after chemotherapy. This case will be added to the few reports describing such changes in PD-L1 expression after different treatment modalities. More data are needed to understand the underlying mechanisms and its treatment implications.




J Med Cases. 2019;10(2):62-65
doi: https://doi.org/10.14740/jmc3249

Keywords


PD-L1; Chemotherapy; Squamous lung cancer

Full Text: HTML PDF
 

Browse  Journals

     

Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.        
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.